Superfluorinated, Highly Water-Soluble Polyphosphazenes as Potential 19F Magnetic Resonance Imaging (MRI) Contrast Agents
Source abstract
Abstract
“Hot spot” 19F magnetic resonance imaging (MRI) has garnered significant attention recently for its ability to image various disease markers quantitatively. Unlike conventional gadolinium-based MRI contrast agents, which rely on proton signal modulation, 19F-MRI’s direct detection has a unique advantage in vivo, as the human body exhibits a negligible background 19F-signal. However, existing perfluorocarbon (PFC) or PFC-based contrast materials suffer from several limitations, including low longitudinal relaxation rates and relatively low imaging efficiency. Hence, we designed a macromolecular contrast agent featuring a high number of magnetically equivalent 19F-nuclei in a single macromolecule, adequate fluorine nucleus mobility, and excellent water solubility. This design utilizes superfluorinated polyphosphazene (PPz) polymers as the 19F-source; these are modified with sodium mercaptoethanesulfonate (MESNa) to achieve water solubility exceeding 360 mg/mL, which is a similar solubility to that of sodium chloride. We observed substantial signal enhancement in MRI with these novel macromolecular carriers compared to non-enhanced surroundings and aqueous trifluoroacetic acid (TFA) used as a positive control. In conclusion, these novel water-soluble macromolecular carriers represent a promising platform for future MRI contrast agents.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lanthanide and Transition Metal Complexes · Advanced MRI Techniques and Applications · Magnetism in coordination complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Polymer Chemistry, Johannes Kepler University Linz, Altenberger Straße 69, 4040 Linz, Austria
Department of Biomedical Imaging and Image-Guided Therapy, Division of Structural and Molecular Preclinical Imaging, Medical University of Vienna and General Hospital of Vienna, 18-20 Währinger Gürtel, 1090 Vienna, Austria
Funding
Austrian Science Fund
References (40)
Show source-provided references
1. Notes on “Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent”10.2214/AJR.07.3549 ↗
2. Gries, H., Rosenberg, D., and Weinmann, H.J. (1987). Paramagnetic complex salts, their preparation, and their use in NMR-diagnostics. (ZA825313B).
3. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent10.2214/ajr.142.3.619 ↗
4. Evaluation of contrast-enhanced MR imaging in a brain-abscess model
5. Top 100 Cited AJR Articles at the AJR’s Centennial10.2214/AJR.05.1186 ↗
6. First use of GdDTPA/dimeglumine in man
7. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers
8. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives10.1007/s12325-015-0275-4 ↗
9. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers10.1021/acs.chemrev.8b00363 ↗
10. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists10.1177/2054358118778573 ↗
11. Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review10.1016/j.ejro.2023.100503 ↗
12. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA’s Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents10.1097/RLI.0000000000000374 ↗
13. Recent Research Progress of 19 F Magnetic Resonance Imaging Probes: Principle, Design, and Their Application10.1002/marc.202200744 ↗
14. Recent Advances in 19Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions10.15302/J-ENG-2015103 ↗
15. Perfluorocarbon Nanoparticles: Evolution of a Multimodality and Multifunctional Imaging Agent10.1155/2014/746574 ↗
16. Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer10.1007/s11307-021-01648-3 ↗
17. 19 F MRI in orthotopic cancer model via intratracheal administration of α ν β 3 -targeted perfluorocarbon nanoparticles10.2217/nnm-2018-0051 ↗
18. Fluorine MR Imaging Probes Dynamic Migratory Profiles of Perfluorocarbon-Loaded Dendritic Cells After Streptozotocin-Induced Inflammation10.1007/s11307-021-01701-1 ↗
19. Polymeric 19 F MRI Contrast Agents Prepared by Ring-Opening Metathesis Polymerization/Dihydroxylation10.1021/acs.macromol.0c01585 ↗
20. Low-Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking10.1002/anie.201914119 ↗
21. Partially Fluorinated Copolymers as Oxygen Sensitive 19 F MRI Agents10.1002/chem.202001505 ↗
22. Preparation of polyphosphazenes: A tutorial review10.1039/C6CS00340K ↗
23. The expanding field of polyphosphazene high polymers10.1039/C5DT03887A ↗
24. Strasser, P., and Teasdale, I. (2020). Main-Chain Phosphorus-Containing Polymers for Therapeutic Applications. Molecules, 25.10.3390/molecules25071716 ↗
25. Alexander, A.K. (2006). Vaccine Adjuvants and Delivery Systems, John Wiley & Sons, Ltd.
26. Chain-End-Functionalized Polyphosphazenes via a One-Pot Phosphine-Mediated Living Polymerization10.1002/marc.201400114 ↗
27. Hetero and homo α,ω-chain-end functionalized polyphosphazenes10.1002/pol.20220066 ↗
28. Translational Research and Early Favorable Clinical Results of a Novel Polyphosphazene (Polyzene-F) Nanocoating10.1007/s40883-019-00097-3 ↗
29. Recent Advances in Polymer Drug Conjugates10.2174/1389557515666150519104507 ↗
30. Polyphosphazene: A New Adjuvant Platform for Cocaine Vaccine Development10.1021/acs.molpharmaceut.2c00489 ↗
31. Degradable Bottlebrush Polypeptides and the Impact of their Architecture on Cell Uptake, Pharmacokinetics, and Biodistribution In Vivo10.1002/smll.202300767 ↗
32. A New High-Yield Synthesis of Cl3PNSiMe3, a Monomeric Precursor for the Controlled Preparation of High Molecular Weight Polyphosphazenes10.1021/ic011125n ↗
33. Polyphosphazene Elastomers with Alkoxy and Trifluoroethoxy Side Groups10.1021/acsapm.9b00913 ↗
34. Application of 19 F NMR Spectroscopy for Content Determination of Fluorinated Pharmaceuticals10.1155/2017/9206297 ↗
35. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths10.1097/01.rli.0000184756.66360.d3 ↗
36. The protein and contrast agent-specific influence of pathological plasma-protein concentration levels on contrast-enhanced magnetic resonance imaging10.1097/RLI.0000000000000061 ↗
37. A Superfluorinated Molecular Probe for Highly Sensitive in Vivo19 F-MRI10.1021/ja503270n ↗
38. Optimization of rapid acquisition with relaxation enhancement (RARE) pulse sequence parameters for ¹⁹F-MRI studies10.1002/jmri.24347 ↗
39. Characterization of perfluorocarbon relaxation times and their influence on the optimization of fluorine-19 MRI at 3 tesla10.1002/mrm.26317 ↗
40. Fluorine polymer probes for magnetic resonance imaging: Quo vadis?10.1007/s10334-018-0724-6 ↗